

- 2014;232:499-508.
106. Moriarty CH, Pursell B, Mercurio AM. MiR-10b targets Tiam1: Implications for Rac activation and carcinoma migration. *J Biol Chem* 2010;285:20541-6.
 107. Joerger AC, Fersht AR. Structure-function-rescue: The diverse nature of common p53 cancer mutants. *Oncogene* 2007;26:2226-42.
 108. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, *et al.* MiR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. *Cancer Res* 2011;71:3552-62.
 109. Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. *RNA Biol* 2009;6:575-83.
 110. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimmer A, *et al.* MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. *Genes Dev* 2011;25:226-31.
 111. Ren Y, Han X, Yu K, Sun S, Zhen L, Li Z, *et al.* MicroRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. *Mol Med Rep* 2014;10:315-21.
 112. Lin J, Liu C, Gao F, Mitchel RE, Zhao L, Yang Y, *et al.* MiR-200c enhances radiosensitivity of human breast cancer cells. *J Cell Biochem* 2013;114:606-15.
 113. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. *Cell Cycle* 2008;7:3112-8.
 114. Castilla MÁ, Díaz-Martín J, Sarrió D, Romero-Pérez L, López-García MÁ, Vieites B, *et al.* MicroRNA-200 family modulation in distinct breast cancer phenotypes. *PLoS One* 2012;7:e47709.
 115. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, *et al.* Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell* 2006;9:435-43.
 116. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, *et al.* MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. *Oncogene* 2014;33:3119-28.
 117. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, *et al.* Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. *BMC Biotechnol* 2007;7:36.
 118. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, *et al.* MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. *J Pathol* 2009;219:214-21.
 119. Bu Y, Lu C, Bian C, Wang J, Li J, Zhang B, *et al.* Knockdown of dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin. *Oncol Rep* 2009;21:13-7.
 120. Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, *et al.* The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). *J Biol Chem* 2013;288:10973-85.
 121. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, *et al.* Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. *Biochem Pharmacol* 2010;79:817-24.
 122. Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, *et al.* MiRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. *Mol Med Rep* 2013;7:1579-84.
 123. Fang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, *et al.* Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. *Braz J Med Biol Res* 2014;47:60-9.
 124. Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. *Gene* 2013;531:8-14.
 125. Sehdev S, Martin G, Sideris L, Lam W, Brisson S. Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. *Curr Oncol* 2009;16 Suppl 2:S14-23.
 126. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, *et al.* Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. *Proc Natl Acad Sci U S A* 2008;105:13021-6.
 127. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, *et al.* MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J Biol Chem* 2008;283:29897-903.
 128. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE, *et al.* Oncogenic HER2{Delta} 16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. *Carcinogenesis* 2010;31:2049-57.
 129. Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, *et al.* MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. *Breast Cancer Res Treat* 2011;127:43-51.
 130. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. MiR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. *J Biol Chem* 2009;284:24696-704.
 131. Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, *et al.* Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. *J Biol Chem* 2009;284:18515-24.